HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Market News Stocks News ETF News Crypto News

Kura Oncology, Inc.

Contributing Author

Recent Articles by Kura Oncology, Inc.

Oct-03
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Oct-01
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) KURA GlobeNewswire
Sep-29
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) KURA GlobeNewswire
Sep-25
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology KURA GlobeNewswire
Sep-24
Kura Oncology to Participate in Upcoming Investor Conference KURA GlobeNewswire
Sep-16
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types KURA GlobeNewswire
Sep-05
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Sep-03
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program KURA GlobeNewswire
Aug-28
Kura Oncology to Participate in Three Upcoming Investor Conferences KURA GlobeNewswire
Aug-07
Kura Oncology Reports Second Quarter 2025 Financial Results KURA GlobeNewswire
Aug-04
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jul-31
Kura Oncology to Report Second Quarter 2025 Financial Results KURA GlobeNewswire
Jul-03
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jun-12
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress KURA GlobeNewswire
Jun-06
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jun-02
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting KURA GlobeNewswire
Jun-01
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML KURA GlobeNewswire
May-22
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting KURA GlobeNewswire
May-20
Kura Oncology to Participate in Three Upcoming Investor Conferences KURA GlobeNewswire
May-14
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress KURA GlobeNewswire
May-06
Kura Oncology to Participate in Bank of America Securities Healthcare Conference KURA GlobeNewswire
May-02
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
May-01
Kura Oncology Reports First Quarter 2025 Financial Results KURA GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.